Glycans or carbohydrates attached to therapeutic glycoproteins can directly affect product quality, safety and efficacy, and therefore must be adequately analyzed and controlled throughout product life cycles. However, the complexity of protein glycosylation poses a daunting analytical challenge. In this study, we evaluated the utility of a lectin microarray for assessing protein glycans. Using commercial lectin chips, which contain 45 lectins toward distinct glycan structures, we were able to determine the lectin binding patterns of a panel of 15 therapeutic proteins, including 8 monoclonal antibodies. Lectin binding signals were analyzed to generate glycan profiles that were generally consistent with the known glycan patterns for these glycoproteins. In particular, the lectin-based microarray was found to be highly sensitive to variations in the terminal carbohydrate structures such as galactose versus sialic acid epitopes. These data suggest that lectin microarray could be used for screening glycan patterns of therapeutic glycoproteins.
Introduction
Glycosylation of proteins is a complex post-translational modification that attaches carbohydrates or named glycans at specific sites on a protein backbone, most commonly at Asn (N-linked) or Ser/Thr (O-linked) residues. 1 The N-linked glycosylation occurs at the consensus sequence of Asn-X-Ser/Thr (where X is any amino acid except proline), whereas O-linked glycans are usually attached to Ser or Thr residues. Both Nand O-glycosylation involve a series of enzymatic reactions catalyzed by glycan-processing enzymes, which are responsible for trimming and modifications of glycan epitopes, resulting in diverse N-glycan structures (e.g., high-mannose, complex, and hybrid glycans) and O-glycan variants containing up to 8 OGalNAc glycan core structures. To add complexity, protein glycosylation is influenced by the type of host cells and fluctuations in fermentation conditions (e.g., media, pH, temperature, agitation). 2 For instance, therapeutic glycoproteins produced by mammalian cells such as Chinese hamster ovary (CHO) cells usually contain human-like glycans. By contrast, proteins expressed by yeast strains usually contain high levels of mannose (up to 100 units). Other hosts including engineered plant cells and genetically modified animals may produce proteins with non-human glycan variants such as xylose, N-glycolylneuraminic acid (Neu5Gc) or terminal a-galactose (a-Gal), which are known to be immunogenic. As a result, a glycoprotein produced by living cell systems usually contains a mixture of different glycoforms. These protein variants share an identical peptide backbone, but may differ in glycosylation properties such as glycosylation site, glycan structure and content.
Glycans attached to a therapeutic protein can directly affect product quality, safety and efficacy. It is well documented that glycans attached to a protein affect protein solubility and stability, [3] [4] [5] pharmacokinetics/pharmacodynamics (PK/PD), 3, [6] [7] [8] and immunogenicity. 2, 9 In the latter, non-human glycans attached onto a therapeutic protein such as Neu5Gc and terminal a-Gal epitopes could cause immunogenic responses. For many monoclonal antibodies (mAbs), proper glycosylation of the crystallizable fragment (Fc) is essential to IgG antibody effector functions. 10 Therefore, glycan moieties of therapeutic proteins must be adequately characterized and controlled throughout product life cycle. The commonly used methods include highperformance liquid chromatography (HPLC), high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD), mass spectrometry (MS) and capillary electrophoresis (CE), [11] [12] [13] [14] [15] [16] which provide information on glycosylation sites, site occupancy, and contents of glycan variants attached to glycoproteins.
There is growing interest in the development of high throughput platforms for assessing protein glycan profiles. Lectins are glycan binding proteins (GBPs) that selectively recognize glycan epitopes of free carbohydrates or glycoproteins. 17 Lectin-based microarrays have been used to analyze glycan profiles of purified glycoproteins or cell surface proteins. [18] [19] [20] [21] [22] [23] In this study, we evaluated the potential utility of a lectin microarray for characterization of therapeutic glycoproteins. Using commercial lectin chips containing 45 distinct lectins, we tested a panel of 15 therapeutic proteins for their glycan profiles. Our data show that the lectin microarray is robust in generating glycan profiles that are generally consistent with the known glycan characteristics of an individual glycoprotein.
Results
The utility of a lectin microarray in determining glycan profiles of therapeutic mAbs
We assessed the utility of a lectin microarray in profiling glycan variants of therapeutic proteins using commercial lectin microchips printed with 45 distinct lectin proteins (Fig. 1A) . These include lectins that selectively bind core-fucose, sialic acids, Nacetyl-D-lactosamine (Galb1-4GlcNAc), mannose, or N-acetylglucosamine (GlcNAc) oligomers, respectively (Table 1) . 18 These glycan structures are commonly found in recombinant glycoproteins. We tested a panel of 15 distinct proteins, including 8 therapeutic mAbs, one Fc-fusion protein, 4 recombinant therapeutic cytokines and enzymes, and 2 different versions of human transferrin proteins (Table 2) . To facilitate microarray analysis, protein samples were fluorescently labeled with Cy3 followed by incubation onto lectin-coated chips. We first performed dose-titrations and identified the optimal concentrations of Cy3-labeled protein sample that fell within the linear response ranges for most lectin spots (Supplement I). We also tested the effect of incubation time on lectin binding signals, showing that overnight incubation is required to obtain optimal binding between a Cy3-labeled glycoprotein and the lectins printed on chips (Supplement II). In the following experiments, a fixed concentration of protein samples (125 ng/mL) was applied to lectin chips and incubated overnight then lectin binding signals were detected. Bound glycoprotein signals were determined using evanescent-field fluorescence scanner, which allows a direct measure of glycans bound onto lectins without the need of washing procedures to remove unbound species (Fig. 1B) . Using lectin chips from different batches, we determined the assay reproducibility to be < 10% CV for most lectin-glycan binding signals of the samples tested.
We first tested a panel of 6 therapeutic mAbs, including bev-
omalizumab (Xolair Ò ). These products are known to be IgG1 isotypes with glycosylation exclusively occurring in the Fc.
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All these IgG1 mAbs showed similar lectin binding patterns ( Fig. 2A & ) and then applied onto the lectin chips. The binding signals at each lectin spots are measured using an evanescent-field fluorescence scanner, detecting the presence or absence of glycan variants in the testing sample based on the known selectivity of lectins toward particular glycan structures.
interactions (Table 1) , the lectin binding patterns indicate the presence of core fucose, outer galactose, mannose, and GlcNAc oligomer, and the absence of sialic acids and tri/tetra-antennary complex-type N-glycans. Overall, the glycan profiles derived from lectin microarray are consistent with the reported glycans in IgG1 Fc that are known to contain principally bi-antennary non-sialylated complex-type N-glycans with little or no highmannose type or sialylation (Fig. 2C ). 27 Using the specified lectin chips, we detected similar lectin binding patterns for IgG1 mAbs containing only Fc glycosylation (Fig. 2B) . Compared to the other 5 mAbs, rituximab appeared to display relative higher binding signals at AOL/AAL (core fucose), RCA120 (terminal galactose), and GNA (high mannose). Panitumumab (Vectibix Ò ), an IgG2 isotype, displayed much weaker signal intensities across the lectin chip despite a similar lectin binding pattern as observed for IgG1 mAbs ( Fig. 2A) . This data is consistent with the reported lower level of glycan content in the IgG2 antibodies in comparison with IgG1 antibodies. 28 ,29
Next, we tested 2 other therapeutic glycoproteins that are associated with more complex glycosylation patterns. Cetuximab (Erbitux Ò ) was chosen because it contains N-glycosylation sites in both the antigen-binding fragment (Fab) and Fc of the molecule. 30 In contrast to glycan profiles for IgG1 mAbs (Fig. 2) , cetuximab showed unique binding patterns at lectins (SNA, SSA and TJA-I), which are known to bind a2-6-linked sialic acids (Fig. 3A & B) . A binding signal was also detected at 
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the a-Gal binding lectin GSL-I-A4, 31, 32 suggesting the presence of a-Gal structures in cetuximab proteins. Such a glycan variant was not detected in other samples tested in this study. Overall, this data is consistent with the known glycan patterns of cetuximab Fab, which include an abundant N-linked sialic acid (Neu5Gc) and terminal a-Gal variants (Fig. 3C ). 30 Another sample tested was etanercept (Enbrel Ò ), a homodimer of Fc-fusion protein consisting of TNF-a receptor and an IgG1 Fc portion, which was reported to contain 3 N-linked and 13 O-linked glycosylation sites. 33 Etanercept displayed distinct lectin binding patterns compared to IgG1 mAbs. For example, strong binding signals were detected at MAL-I and ACG, which are known to selectively bind a2-3 linked sialic acid epitope. No signals were detected at lectins SNA, SSA or TJA-1, showing the lack of a2-6 sialylation in the protein sample. 34 This data confirms the presence of complex glycans in etanercept, including a2-3-sialic acids and abundant bi-antennary neutral glycans. Compared to other IgG1 mAbs, etanercept displayed a strong and novel signal at MPA, a lectin that is known to selectively bind Galb1-3GalNAc and aGalNAc. 35 This data is consistent with the reported abundance of O-glycans onto etanercept. 33 To support the selectivity of lectin binding signals, we tested the Fab and Fc purified from rituximab and cetuximab, respectively. Rituximab is known to contain only one N-glycosylation site in its Fc. 26 In the lectin microarray, the isolated rituximab Fab showed little or no signals across the lectin chip whereas the rituximab Fc displayed a similar lectin profile as intact rituximab (Fig. 4A) . By contrast, cetuximab contains 2 N-glycans, one located within its Fc portion and another in the Fab. 30 The uncommon a-Gal and Neu5Gc epitopes were reported to be solely in the Fab (Fig. 3C) . 30 The cetuximab Fc expressed a typical lectin profile for IgG1 Fc glycans (bi-antennary G0F, G1F, and G2F) (Fig. 4B) . The lectin signals of SNA, SSA and TJA-1, which indicate expression of a2-6-sialylation, were only present in intact cetuximab and cetuximab Fab profiles, but were absent in the Fc profile. GSL-I signal also indicated the presence of a-Gal structure in the Fab, but not in the Fc (Fig. 4B) . These data not only confirm the proper locations of glycosylation sites in Fc or Fab portions, but also support the selectivity of lectin bindings toward particular glycans in a testing sample. As noted, the rituximab Cy3-labeled Fab showed no lectin-binding signals across the lectin chips, confirming no or little interaction between the protein backbone and the lectins.
The utility of lectin microarray in glycan profiling of proteins produced by different host cell systems
We assessed whether lectin microarray is capable of profiling glycan variants of therapeutic proteins that are produced by different host cell systems such as mammalian cells, yeast strains and bacterial strains. These cell systems are different in their glycosylation machinery, which produce proteins with distinct glycan patterns. For example, glycoproteins expressed by yeast strains usually contain high-mannose structures whereas Escherichia coli (E. coli) proteins are all non-glycosylated due to the lack of glycosylation machinery in natural bacterial. 2 We evaluated a panel of 6 proteins, including 2 therapeutic proteins produced by CHO cells (darbepoetin alfa (Aranesp Ò ) and dornase alfa (Pulmozyme Ò )), one therapeutic protein produced by yeast (rasburicase (Elitek Ò )), human transferrin proteins expressed by recombinant rice strain or isolated from human plasma, and filgrastim (Neupogen Ò ) produced by E. coli (Fig. 5A & B) . Darbepoetin alfa showed strong signals at MAL-I, demonstrating the presence of a2-3-sialylation structures. Moreover, darbepoetin alfa displayed strong signals at PHALcoated spots, which are known to be selective for tri-/tetraantennary N-glycan structures. Such a signal was not detected in other proteins, confirming the absence of tri-/tetra-antennary glycans in these samples. This pattern was consistent with the reported data that darbepoetin alfa contains high levels of sialylation and abundant tri-or tetra-antennary structures (Fig. 5C ). 36 Darbepoetin displayed relative week binding signals at other lectin spots compared to MAL-I and PHAL, raising a possibility that those other glycan species (e.g., Galb1-4GlcNAc and mannose oligomers) might be "capped" by the outermost galactose and sialic acid.
Dornase alfa (Pulmozyme Ò ), a recombinant enzyme expressed by CHO cells, displayed a simpler lectin binding pattern compared to the above IgG1 and IgG2 mAbs ( Fig. 5A and 27 5B). The sample tested showed unique binding signals at SNA/ SSA for a2-6-sialylation, RCA120 for Galb1-4GlcNAc, DSA for GlcNAc oligomer and/or Galb1-4GlcNAc, 37, 38 ConA for mannose, and LEL/STL for GlcNAc oligomers. The spectrum of selective binding signals suggests the presence of complextype glycans with a2-6-sialylation in dornase alfa molecules. By contrast, rasburicase (Elitek Ò ), a therapeutic glycoprotein produced by yeast strains, displayed distinctively different lectin profiles compared to the above described products produced by mammalian cells. Rasburicase showed relatively weak binding signals across the lectin chips, which is consistent with its known low level of glycosylation. 39 Despite the overall weak binding signals, rasburicase appeared to interact exclusively with mannose binding lectins (NPA, ConA, and GNA) and GlcNAc oligomer binding lectins (STL and UDA). This data confirms the presence of high-mannose carbohydrates that are mainly attached onto glycoproteins produced by yeast strains. 40 No binding signals were detected at sialic acid-binding lectins (e.g., MAL_I, SNA, SSA, and TJA-I), fucose-binding lectins (e.g., PSA and LCA) or galactose-binding lectins (e.g., RCA 120 and PHAE), even when the protein concentration of rasburicase was enhanced to 500 ng/mL (data not shown), demonstrating the absence of the relevant glycan species in rasburicase. The two versions of human transferrin proteins also showed distinct glycan patterns in which the recombinant human transferrin expressed in rice (transferrin-rice) showed binding signals primarily at mannose-binding lectin (NPA) and GlcNAc oligomer-binding lectins (LEL, STL and UDA). The DSA signal indicated the presence of either GlcNAc oligomer or Galb1-4GlcNAc. By contrast, transferrin proteins isolated from human plasma showed additional signals at a2-6-sialic acid-binding lectins (SNA, SSA, and TJA-I) and galactose-binding lectins (RCA120 and PHAE). As expected, no lectin binding signals were detected for filgrastim (Neupogen Ò )
that is produced by E. coli as a non-glycosylated protein. 41 The utility of lectin microarray in monitoring terminal galactosylation and sialylation of glycoproteins
To further evaluate the utility of lectin microarray in glycan profiling, we prepared protein variants with defined galactosylation and sialylation modifications. This was achieved through in vitro enzymatic glycoengineering of rituximab using commercially available galactosyltransferase and sialyltransferase. b1-4-galactosyltransferase (b1-4GalT) catalyzes the transfer of galactose from donor substrate UDP-galactose (UDP-Gal) to GlcNAcb1-2Man units of glycoproteins to form a b1-4-galactosylation linkage, while a2-6-sialyltransferase (a2-6SiaT) facilitates sialylation by adding sialic acids to terminal Galb1-4GlcNAc units. Modified rituximab protein variants were purified and then characterized using mass spectrometry (MS), revealing distinct deconvoluted MS spectra for the light chain and heavy chain (Fig. 6A) . The light chain fragments resolved as a single species at an average mass of 23036 Da, corresponding to the theoretical mass of rituximab light chain. 42, 43 Consistent with the lack of glycosylation sites within the rituximab light chains, the mass of light chain remained unchanged after treatments of rituximab with b1-4GalT or further with a2-6SiaT. The other 3 major mass species at 50507, 50669, 50832 Da correspond to the heavy chains of rituximab containing G0F, G1F or G2F glycoforms, respectively (Fig. 2C) . 42, 43 Treatment of rituximab with b1-4GalT resulted in a mass shift from G0F and G1F to G2F, indicating galactosylation reactions were effectively accomplished. When the galactosylated rituximab mixture was sequentially treated with a2-6SiaT, the final product showed a further mass shift from 50832 Da (G2F) to 51122 Da (C290) and 51414 Da (C582). These mass shifts corresponded to an addition of one or two Neu5Ac residues, indicating that G2F glycoform was effectively converted to primarily mono-sialylated species (S1G2F) and a small portion of di-sialylated species (S2G2F). These data indicate that the in vitro glycan engineering reactions produced rituximab variants containing the desired modifications (e.g., galactosylation and sialylation).
The engineered rituximab samples with defined glycan variations were then analyzed by lectin microarray (Fig. 6B) . The reaction buffer alone had no effect on lectin binding profile of rituximab. The sample resulting from b1-4GalT reaction (rituximab C b1-4GalT), which was confirmed by MS to majorly contain G2F galactosylation (Fig. 6A) , displayed strong binding signals at positions of ECA and RCA120. Both lectins are known to bind N-glycan Galb1-4GlcNAc, and therefore the incurred ECA lectin-binding signal and the significantly enhanced RCA120 signal were indicative of the increased galactose species in the samples. Notably, there was a concomitant decrease in the binding signals at ABA, a lectin with dual binding affinity toward Gal-exposed O-glycans and GlcNAcexposed N-glycans. 44 Because rituximab was not reported to undergo O-glycosylation, the ABA binding signal detected for native rituximab was likely due to GlcNAc-exposed N-glycans. Such GlcNAc-exposed N-glycans appeared to be occupied upon galactosylation catalyzed in the reactions with b1-4GalT. Samples of native rituximab and galactosylated species showed no detectable signals at the lectins SNA, SSA, TJA-I that are known to bind sialic acids. By contrast, strong binding signals at these lectins were detected for the samples derived from the sequential reactions with b1-4GalT and a2-6SiaT enzymes. No signal was detected at MAL-I (a lectin selective to a2-3-sialylation), demonstrating not only the specificity of glycan engineering but also the utility of the lectin microarray in distinguishing different terminal sialic acid linkages.
Discussion
The complexity of glycosylation poses an analytical challenge in the development of therapeutic glycoproteins. The methods most commonly used for analysis include MS, HPLC, HPAEC-PAD, and CE. Among these methods, MS remains a powerful tool in the characterization of glycosylation site(s) occupancy and carbohydrate structures. MS-based methods involve enzymatic digestion of a glycoprotein into peptide fragments and separation by liquid chromatography. HPLC-, HPAEC-and CE-based methods usually require the release of glycans from a glycoprotein through enzymatic or chemical reactions. As such, an accurate assessment of glycosylation requires a complete release of all glycans that are present in a glycoprotein being tested. By contrast, lectin microarray directly measures glycan profiles on an intact protein without the need for enzymatic digestion or clipping glycans from the protein backbone. Such a platform is unique in increasing the likelihood of full coverage of all glycan variants of a glycoprotein. Using the commercial lectin chips, we were able to determine glycan profiles for a panel of therapeutic proteins that were generally consistent with their known glycosylation properties (Figs. 2-5) . Notably the lectin microarray was highly sensitive to alterations in the terminal glycan structures, i.e., galactosylation vs. Figure 6 . Assessing glycan variants in glycan-engineered rituximab protein samples. Rituximab was incubated with a reaction buffer alone (rituximab C buffer), b1-4-galactosyltransferase (rituximab C b1-4GalT), and b1-4-galactosyltransferase followed by a2-6-sialyltransferase (rituximab C b1-4GalT C a2-6SiaT) (see detail in Materials and Methods). After affinity purification, the resulting samples were analyzed using mass spectrometry and lectin microarray, respectively. Shown are representatives of deconvoluted mass spectra (A) and corresponding lectin binding profiles (B) for the samples produced under the indicated conditions. sialyation (Fig. 6) . Lectin microarray can effectively distinguish glycan isomers containing different sialic acid linkages. Our data demonstrate a usefulness of the lectin microarray in screening glycan patterns of protein samples. As noted, the commercial lectin chips employed in this study was not designed specifically for assessing therapeutic mAbs. In principle, assay performance could be further improved through the use of lectins with improved selectivity and binding affinity to distinct glycan species. To analyze a specific glycoprotein, lectin chips can be customized to include the lectins that are relevant to the glycan species that are possibly present in the testing sample. Upon optimization of lectin chips, lectin microarray platform could be adopted as a complementary tool for high throughput screening of glycan profiles of therapeutic glycoproteins.
Materials and methods

Therapeutic proteins and reagents
All therapeutic proteins were purchased from the Division of Veterinary Resources pharmacy, Office of Research Services, National Institute of Health, and handled according to respective package inserts. Recombinant human transferrin expressed by rice and transferrin purified from human blood plasma were purchased from Sigma-Aldrich. Cy3 mono-reactive dye was obtained from GE Healthcare. Zeba spin desalting columns (7K MWCO) were purchased from Thermo Scientific. Lectin chips coated with 45 distinct lectin proteins and the probing solutions were obtained from GlycoTechnica. Glycosyltransferases b1-4-galactosyltransferase (b1-4GalT) and a2-6-sialyltransferase (a2-6SiaT) were purchased from Prozyme. Micro BCA Protein Assay Kit, NAb Protein A Plus Spin Kit and Pierce Fab micro preparation kit were obtained from Thermo Scientific. NuPAGE 4-12% Bis-Tris gels and Coomassie stain (SimplyBlue SafeStain) were purchased from Life Technologies.
Lectin microarray analysis
Protein samples were diluted to 50 mg/mL in phosphate-buffered saline (PBS). Aliquots (20 mL, 1 mg protein) were mixed with 100 mg Cy3 mono-reactive dye, and incubated at room temperature for 2 h. The unbound Cy3 dye was removed using Zeba spin desalting columns (7K MWCO). Cy3-labeled protein samples were diluted to 125 ng/mL in probing solution, and an aliquot of 100 mL was applied onto a lectin chip, and incubated at room temperature on an orbital shaker for 18 hours in dark. The resulting lectin chips were scanned for fluorescence intensities on each lectin-coated spot using an evanescent-field fluorescence scanner GlycoStation Reader 1200 (GlycoTechnica, Japan).
Preparation of IgG Fab and Fc
The Fab and Fc of therapeutic mAbs were prepared using Pierce Fab micro preparation kit following the vendor's protocol (Thermo Scientific). Briefly, immobilized papain (settled resin) was located in a 0.8 mL spin column and equilibrated using Fab digestion buffer. Antibody samples were diluted to 0.4 mg/mL using Fab digestion buffer, and aliquot of 120 mL was added to the spin column containing equilibrated immobilized papain. The digestion reaction was incubated overnight at 37 C. Digested samples were collected by column centrifugation and applied onto NAb Protein A Plus Spin Column to separate the Fab and Fc. Protein concentrations of the resulting samples were determined using Micro BCA Protein Assay Kit (Thermo Scientific).
Enzymatic glycan engineering of rituximab
Rituximab was used to create glycan variants of a mAb through in vitro enzymatic reactions. Briefly, rituximab stock solution was diluted to 2 mg/mL using 1£ galactosyltransferase (GalT) reaction buffer (10 mM MnCl 2 with 100 mM MES, pH 6.5). Uridine-5'-diphosphogalactose disodium salt (UDP-Gal) solution (50 mg/mL) was also prepared using 1£ GalT reaction buffer. Cytidine 5'-monophospho-N-acetylneuraminic acid disodium salt (CMP-Neu5Ac) solution (50 mg/mL) was prepared using 1£ sialyltransferase (SiaT) reaction buffer (50 mM Tris-Acetate, pH 7.5). To facilitate galactosylation, 50 mL rituximab (2 mg/mL in solution) was mixed with 4 mL UDP-Gal (50 mg/mL in solution) and 1.5 mg b1-4-galactosyltransferase (b1-4GalT). The final reaction volume was adjusted to 100 mL using 1£ GalT reaction buffer, and was left to incubate overnight at 37 C, resulting galactosylation of rituximab. To further add sialylation, the above galactosylated rituximab was mixed with 200 mg CMP-Neu5Ac (50 mg/mL in solution) and 10 mg a2-6-sialyltransferase (a2-6SiaT). After adjusting volume to 200 mL using 1£ SiaT reaction buffer, the mixture was incubated at 37 C for 3 hours and then frozen at ¡20 C. The engineered antibodies containing different glycan variants were purified using NAb Protein A Plus Spin Kit by following the protocol instructions (Thermo Scientific).
Liquid chromatography-mass spectrometry analysis
Liquid chromatography-mass spectrometry analyses were conducted on an Agilent 1260 HPLC-Chip nano-electrospray-ionization 6520 Q-TOF MS system. Solvent-A was 0.1% formic acid in water and solvent-B was 0.1% formic acid in 95% acetonitrile. Mass correction was enabled during the run using internal reference ions with masses of 299.2945 and 1221.9906 Da. Intact protein mass measurement was performed using an Agilent 43 mm 300 A C8 chip with a 40 nL trap column (G4240-63001 SPQ105). All rituximab samples were reduced in 10 mM DTT for 1 hour at 37 C, and then formic acid was added to reach a final concentration of 0.1% (V/V). The samples were diluted to 150 ng/mL in 0.1% formic acid, and 1 mL (1 pmol) or larger volume was injected onto the trap column in the C8 chip at a flow rate of 2.5 mL/min in 100% A, then eluted at 0.5 mL/ min with a linear gradient of 10-100% B in 18 min and held for additional 4 min. Q-TOF VCap, fragmentor, and skimmer settings were 1,890 eV, 225 eV, and 65 eV, respectively. HPLCChip gas temperature and drying gas flow rate were 350 C and 9 L/min, respectively. The data were analyzed using Agilent MassHunter (version B.05.00) Qualitative Analysis software and deconvoluted with Agilent MassHunter Bioconfirm software.
